Profile data is unavailable for this security.
About the company
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
- Revenue in USD (TTM)71.30m
- Net income in USD-354.80m
- Incorporated2014
- Employees445.00
- LocationArvinas Inc5 Science ParkNEW HAVEN 06511-1966United StatesUSA
- Phone+1 (203) 535-1456
- Fax+1 (302) 636-5454
- Websitehttps://www.arvinas.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.20bn | 383.00 | -- | 2.96 | -- | 74.94 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.20bn | 624.00 | -- | 14.34 | 462.27 | 7.78 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.63 | -- | 12.61 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.21bn | 226.00 | -- | 35.85 | -- | 24.02 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.25bn | 16.00k | -- | 1.42 | -- | 0.7492 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.32bn | 497.00 | -- | 6.40 | -- | 8.71 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.33bn | 314.00 | 5,017.78 | 9.94 | 431.75 | 11.22 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.33bn | 160.00 | -- | 2.78 | -- | 384.04 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.40bn | 1.45k | -- | 6.68 | -- | 4.57 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.41bn | 445.00 | -- | 3.95 | -- | 33.83 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.45bn | 64.00 | -- | 3.74 | -- | 336.28 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.47bn | 919.00 | -- | 4.41 | -- | 8.91 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.49bn | 610.00 | -- | 5.36 | 278.75 | 3.06 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 2.52bn | 253.00 | -- | 3.03 | -- | 231.57 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.60bn | 284.00 | 76.42 | 16.27 | 62.95 | 9.00 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to Arvinas Inc's reporting currency: US Dollar USD
53.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Mar 2024 | 6.73m | 9.85% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.14m | 9.00% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.40m | 6.44% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 4.26m | 6.24% |
| RTW Investments LPas of 31 Mar 2024 | 3.30m | 4.83% |
| Avidity Partners Management LPas of 31 Mar 2024 | 2.99m | 4.37% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.61m | 3.83% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 2.39m | 3.50% |
| Citadel Advisors LLCas of 31 Mar 2024 | 2.21m | 3.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.38m | 2.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
